Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Press release 2023-04-19, Press release 2022-11-15, Press release 2022-10-27, In Person Lunch & Learn | Process Characterization, Paveway PLUS Microbial Expression Platform, FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies. Under the terms of the deal, Atara will receive USD 100 million at closing and Fujifilm plans to offer positions to approximately 140 current highly skilled manufacturing and quality staff at the site. Pipeline, Stories of As part of a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Ataras promising clinical and commercial-stage allogeneic cell therapies at the site, including tabelecleucel (tab-cel), currently in phase 3 clinical development and under review to support registration in Europe, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. QIMR Berghofer In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. reserved. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras proposed sale of its ATOM manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the parties ability to consummate such transaction, including the timing thereof, the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the proposed supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the proposed supply agreement and meet Ataras requirements, FDBs potential plans for ATOM, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. ATOM is a 90,000 ft cutting edge T-cell therapy manufacturing facility fully qualified to support clinical and commercial production and designed with the flexibility to expand to support various production requirements and capacities. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell. The upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. +1 979 431 3500, Biotek All 1 Alex Chapman Strength, Multiple Explore patient stories, our clinical studies, HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston, and London. For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras sale of its manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the supply agreement and meet Ataras requirements, FDBs plans for the manufacturing facility, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. Atara Biotherapeutics, Inc. (Nasdaq: ATRA) has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty (HCRx) for Ebvallo in Europe and other territories covered by Atara's commercialization agreement with Pierre Fabre. Through this acquisition Fujifilm can extend its CDMO offering to advanced cell therapies. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Media Atara Biotherapeutics, Inc. . FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. Studies, Expanded FUJIFILM Corporation has invested over USD 5.5 billion to grow the Bio CDMO business unit in order to provide our customers with long-term support across a full-range of modalities, and manufacturing scales, said Takatoshi Ishikawa, senior executive vice president, general manager Bio CDMO Division, FUJIFILM Corporation. The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. or visit our investor hub for more information. 805-395-9669 Project management for Global Recruitment Campaign. Powered by Madgex Job Board Software, https://www.businesswire.com/news/home/20220401005459/en/, http://www.businesswire.com/news/home/20220401005459/en. At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. Leading Global rewards project planning and execution. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. Were the first company ever to receive an approval for an allogeneic T-cell immunotherapy. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. +1 805 699 5579, 300 N. Beacon Street, United States of America 805-456-4772 Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. +1 919 337 4400, Belasis Avenue Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. The ability to identify and leverage synergies between its businesses is a key strength of Fujifilm and fundamental to its growth strategy. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Billingham, TS23 1LH FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress, Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty, Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD. Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. This acquisition is expected to be completed in April 2022, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. United States of America Denmark FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB). This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. 04:05PM. College Station, TX 77845 Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Christine Jackman Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. A live audio webcast can be accessed by visiting the Investors & Media News & Events section of www.atarabio.com. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc.,(Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Ataras cell therapy manufacturing facility in Thousand Oaks, California for USD 100 million upfront and the commencement of a long-term strategic supply agreement. This press release contains or may imply forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Eric Hyllengren Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005459/en/, INVESTORS & MEDIA: SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- For more information, please visit: https://www.fujifilmholdings.com. The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032. With the closing of the transaction, FUJIFILM Diosynth Biotechnologies will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. 805-456-4772 805-456-4772 To be the leading and most trusted global Contract Development and Manufacturing Organization in the biopharmaceutical industry. This acquisition is expected to be completed in April 2022, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. Full-Time. Information for ehyllengren@atarabio.com Atara will retain its expertise, staff, and capabilities in manufacturing process science to continue to innovate in initial manufacturing and scale up for allogeneic cell therapies. In its pursuit to establish itself as a comprehensive healthcare company covering prevention, treatment and diagnosis, FUJIFILM Corporation has made multiple strategic acquisitions over recent years to expand and diversify its healthcare portfolio. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.
Maac Basketball Coaches Salaries,
Difference Between Living Things And Non Living Things,
Bangor Crematorium List Of Funerals,
Similes To Describe A Princess,
Articles A